4.5 Article

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1

Related references

Note: Only part of the references are listed.
Article Oncology

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Dan You et al.

Summary: This study identified a novel, potent, and selective HPK1 small molecule kinase inhibitor called Compound K (CompK), which significantly improved human T-cell immune responses in the tumor microenvironment and showed significant synergy with anti-PD-1 therapy. Animal model studies demonstrated improved immune responses and antitumor efficacy with CompK in combination with anti-PD-1, suggesting its potential as a novel pharmacological agent for cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Biochemistry & Molecular Biology

Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer

Ping Wu et al.

STRUCTURE (2019)

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

Article Chemistry, Medicinal

Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors

Rajeev S. Bhide et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)

Review Medicine, General & Internal

Cancer immunotherapy: the beginning of the end of cancer?

Sofia Farkona et al.

BMC MEDICINE (2016)

Article Multidisciplinary Sciences

Tissue-based map of the human proteome

Mathias Uhlen et al.

SCIENCE (2015)

Article Chemistry, Medicinal

Oxadiazoles in Medicinal Chemistry

Jonas Bostrom et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)